Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | GRK5 | P34947 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276893 | 0.84 | KDM4E (0.39) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL31609391 | 0.79 | ALOX15 (0.43) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL28939756 | 0.71 | ALOX15 (0.37) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL2005730 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL4397520 | 0.70 | KDM4E (0.41) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL10514874 | 0.70 | ALOX15 (0.46) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL16915952 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL2005732 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL28564397 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1GAAHPGD | |
| SCHEMBL28372316 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117835980-A | Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof | 朗多生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| CN-115485272-A | PLXDC2 ligands | 朗多生物制药股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-11459310-B2 | LANCL ligands | LANDOS BIOPHARMA, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022087146-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220127250-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20060009439-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20050245514-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1548121-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1541570-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE | MERCIAN CORPORATION (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| EP-0483851-B1 | Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives | MITSUBISHI CHEM CORP (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5128350-A | PYRAZOLYL ACRYLIC ACID DERIVATIVES AND AGRICULTURAL/HORTICULTURAL FUNGICIDES CONTAINING SAID DERIVATIVES | MITSUBISHI KASEI CORPORATION (JP) | 1992-07-07 | — | — | US | disclosed |
| EP-0483851-A1 | Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives | Mitsubishi Chemical Corporation (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245514-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | ALOX15 3033/4885KDM4E 4239/4885ALDH1A1 133/4885 |
| US-20220127250-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | ALOX15 1739/4885KDM4E 3554/4885ALDH1A1 4156/4885 |
| US-20060009439-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | ALOX15 2079/4885KDM4E 3533/4885ALDH1A1 108/4885 |
| US-11459310-B2 | LANCL ligands | LANCL2, LANCL1, ACSL1 | ALOX15 1177/4885KDM4E 3796/4885ALDH1A1 3541/4885 |
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | ALOX15 283/4885KDM4E 855/4885ALDH1A1 1391/4885 |
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | ALOX15 1739/4885KDM4E 3554/4885ALDH1A1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.